Actively Recruiting
T-cell Developmental Status in Patients With Malignant Hematological Tumors
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-07-23
75
Participants Needed
1
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the immune status and prognosis of patients with malignant hematological tumors, thereby guiding clinical therapeutic strategies.
CONDITIONS
Official Title
T-cell Developmental Status in Patients With Malignant Hematological Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older; both genders included; expected survival more than 3 months
- Patients with newly diagnosed or relapsed B-cell lymphoma confirmed by histopathology, bone marrow pathology, flow cytometry, morphology, and genetic testing
- Patients with newly diagnosed or relapsed multiple myeloma confirmed by histopathology, bone marrow pathology, flow cytometry, morphology, and genetic testing
- Healthy volunteers
- Able to understand and voluntarily sign the informed consent form
You will not qualify if you...
- Chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) less than 50% of predicted normal value
- Moderate or severe persistent asthma within the past 2 years, or currently uncontrolled asthma of any severity
- Symptomatic congestive heart failure (NYHA Class II-IV), symptomatic or uncontrolled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) greater than 500 ms at screening
- History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonitis, or severely impaired lung function
- HIV infection (positive HIV-1/2 antibodies) or known syphilis infection
- Unhealed wounds, fractures, gastroduodenal ulcers, persistent fecal occult blood positivity, ulcerative colitis, or other conditions at risk of gastrointestinal bleeding or perforation
- Severe neurological or psychiatric disorders, immunodeficiency, hepatitis or cirrhosis, or other conditions deemed unsuitable for study participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhijuan Lin
Xiamen, Fujian, China, 361000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here